Leonie C P Banning1, Inez H G B Ramakers2, Sebastian Köhler1, Esther E Bron3, Frans R J Verhey1, Peter Paul de Deyn4, Jurgen A H R Claassen5, Huiberdina L Koek6, Huub A M Middelkoop7, Wiesje M van der Flier8, Aad van der Lugt3, Pauline Aalten1. 1. Department of Psychiatry and Neuropsychology (LCPB, IHGBR, SK, FRJV, PA), Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, the Netherlands. 2. Department of Psychiatry and Neuropsychology (LCPB, IHGBR, SK, FRJV, PA), Maastricht University, School for Mental Health and Neuroscience, Alzheimer Center Limburg, Maastricht, the Netherlands. Electronic address: i.ramakers@maastrichtuniversity.nl. 3. Departments of Radiology and Nuclear Medicine (EEB, AVDL), Erasmus MC - University Medical Center, Rotterdam, the Netherlands. 4. Department of Neurology (PPDD), Alzheimer Center, University of Groningen, University Medical Center, Groningen, the Netherlands. 5. Department of Geriatric Medicine (JAHRC), Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behavior, Radboud University Medical Center, Nijmegen, the Netherlands. 6. Department of Geriatrics (HLK), University Medical Center Utrecht, Utrecht, the Netherlands. 7. Department of Neurology and Neuropsychology (HAMM), Leiden University Medical Center, Leiden, the Netherlands. 8. Alzheimer Center Amsterdam, VU University Medical Center (WMVDF), Amsterdam, the Netherlands.
Abstract
OBJECTIVE: To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatric symptoms. METHODS: Data from two large cohort studies, the Dutch Parelsnoer Institute - Neurodegenerative Diseases and the Alzheimer's Disease Neuroimaging Initiative was used, including subjects with subjective cognitive decline (N = 650), mild cognitive impairment (N = 887), and Alzheimer's disease dementia (N = 626). Cerebrospinal fluid (CSF) levels of Aβ42, t-tau, p-tau, and hippocampal volume were associated with neuropsychiatric symptoms (measured with the Neuropsychiatric Inventory) using multiple logistic regression analyses. The effect of the Mini-Mental State Examination (as proxy for cognitive functioning) on these relationships was assessed with mediation analyses. RESULTS: Alzheimer's disease biomarkers were not associated with depression, agitation, irritability, and sleep disturbances. Lower levels of CSF Aβ42, higher levels of t- and p-tau were associated with presence of anxiety. Lower levels of CSF Aβ42 and smaller hippocampal volumes were associated with presence of apathy. All associations were mediated by cognitive functioning. CONCLUSION: The association between Alzheimer's disease pathology and anxiety and apathy is partly due to impairment in cognitive functioning.
OBJECTIVE: To investigate the relationship between Alzheimer's disease biomarkers and neuropsychiatric symptoms. METHODS: Data from two large cohort studies, the Dutch Parelsnoer Institute - Neurodegenerative Diseases and the Alzheimer's Disease Neuroimaging Initiative was used, including subjects with subjective cognitive decline (N = 650), mild cognitive impairment (N = 887), and Alzheimer's disease dementia (N = 626). Cerebrospinal fluid (CSF) levels of Aβ42, t-tau, p-tau, and hippocampal volume were associated with neuropsychiatric symptoms (measured with the Neuropsychiatric Inventory) using multiple logistic regression analyses. The effect of the Mini-Mental State Examination (as proxy for cognitive functioning) on these relationships was assessed with mediation analyses. RESULTS:Alzheimer's disease biomarkers were not associated with depression, agitation, irritability, and sleep disturbances. Lower levels of CSF Aβ42, higher levels of t- and p-tau were associated with presence of anxiety. Lower levels of CSF Aβ42 and smaller hippocampal volumes were associated with presence of apathy. All associations were mediated by cognitive functioning. CONCLUSION: The association between Alzheimer's disease pathology and anxiety and apathy is partly due to impairment in cognitive functioning.
Authors: Shefali Chaudhary; Simon Zhornitsky; Herta H Chao; Christopher H van Dyck; Chiang-Shan R Li Journal: J Alzheimers Dis Date: 2022 Impact factor: 4.160
Authors: Willem S Eikelboom; Esther van den Berg; Ellen H Singleton; Sara J Baart; Michiel Coesmans; Annebet E Leeuwis; Charlotte E Teunissen; Bart N M van Berckel; Yolande A L Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Rik Ossenkoppele; Janne M Papma Journal: Neurology Date: 2021-08-19 Impact factor: 9.910